Catalyst Pharmaceuticals Revenue and Competitors

Claim your profile

Miami, FL USA



Total Funding



Estimated Revenue & Valuation

  • Catalyst Pharmaceuticals's estimated annual revenue is currently $17.3M per year.(i)
  • Catalyst Pharmaceuticals's estimated revenue per employee is $201,000

Employee Data

  • Catalyst Pharmaceuticals has 86 Employees.(i)
  • Catalyst Pharmaceuticals grew their employee count by 12% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation

Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis (MuSK-MG) and spinal muscular atrophy (SMA) Type 3. Catalyst's new drug application for Firdapse® (amifampridine) 10 mg tablets for the treatment of adults with LEMS was recently approved by the U.S. Food & Drug Administration ("FDA"), and Firdapse is now commercially available in the United States. Prior to its approval, Firdapse for LEMS had received breakthrough therapy designation and orphan drug designation from the FDA. Firdapse is currently being evaluated in clinical trials for the treatment of CMS, MuSK-MG and SMA Type 3 and has received Orphan Drug Designation from the FDA for CMS and myasthenia gravis. Firdapse (amifampridine) 10 mg tablets is the first and only approved drug in Europe for the symptomatic treatment in adults with LEMS.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Catalyst Pharmaceuticals News

2022-04-20 - Catalyst Pharmaceuticals to Report First Quarter 2022 ...

Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel...

2022-04-20 - Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives ...

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with...

2022-04-17 - Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors

Shares of Catalyst Pharmaceuticals Inc. CPRX, -2.72% slipped 2.72% to $8.24 Thursday, on what proved to be an all-around dismal trading...

2019-09-03 - Catalyst Pharmaceuticals (NASDAQ:CPRX) Reaches New 1 ...

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX)'s share price reached a new 52-week high on Friday . The stock traded as high as $6.69 and ...

2019-09-03 - Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX): It's A Good ...

Intraday Trading of Catalyst Pharmaceuticals, Inc.: If one intends to pursue a career as a trader, then one must understand and choose between ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding